Tumor Markers, Biological

• 

  Subject Areas on Research

  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A phase I surrogate endpoint study of SU6668 in patients with solid tumors. 
  • Alveolar soft-part sarcoma: a review and update. 
  • Biomarkers in castration-resistant prostate cancer. 
  • Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. 
  • CD34 and α smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. 
  • Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. 
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer. 
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. 
  • Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). 
  • Diagnostic strategies for unknown primary cancer. 
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • Epithelioid and epithelial neoplasms of bone. 
  • Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. 
  • Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Fibrosarcoma-like lipomatous neoplasm: a reappraisal of so-called spindle cell liposarcoma defining a unique lipomatous tumor unrelated to other liposarcomas. 
  • Genetic variants in predicting aggressive prostate cancer: "ready for prime time?". 
  • Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. 
  • Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. 
  • Image-based determination of 'physiomarkers' for personalized cancer therapy. 
  • Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy. 
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. 
  • Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. 
  • Molecular signatures of thyroid follicular neoplasia. 
  • Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. 
  • Overexpression of synuclein-gamma in pancreatic adenocarcinoma. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. 
  • RE: net risk reclassification P Values: valid or misleading? 
  • Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. 
  • Relative quantification based on logistic models for individual polymerase chain reactions. 
  • Reply: To PMID 25432832. 
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. 
  • Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. 
  • Surrogate markers in antiangiogenesis clinical trials. 
  • The current clinical value of the DCIS Score. 
  • The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. 
• 

  Keywords of People

  • Abbruzzese, James, Charles Johnson, M.D. Professor of Medicine, Medicine, Medical Oncology
  • Badea, Cristian Tudorel, Associate Professor in Radiology, Radiology
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology
  • Chitneni, Satish K., Assistant Professor of Radiology, Radiology
  • Clyde, Merlise, Professor of Statistical Science, Statistical Science
  • Esclamado, Ramon Mitra, Richard Hall Chaney,Sr. Professor of Otolaryngology, Head & Neck Surgery, in the School of Medicine, Surgery, Head and Neck Surgery and Communication Sciences
  • Gottlin, Elizabeth B., Assistant Professor in Radiology, Radiology, Cardiothoracic Imaging
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Hartemink, Alexander J., Professor in the Department of Computer Science, Computer Science
  • Hirschey, Matthew, Associate Professor in Medicine, Pharmacology & Cancer Biology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Pharmacology & Cancer Biology
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Myers, Evan Robert, Walter L. Thomas Professor of Obstetrics and Gynecology in the School of Medicine, Obstetrics and Gynecology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Setton, Lori A., Adjunct Professor of Biomedical Engineering, Biomedical Engineering
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology, Nuclear Medicine
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Woodward, Julie Ann, Associate Professor of Ophthalmology, Dermatology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology